Investing.com -- Denali Therapeutics (NASDAQ:DNLI), a biopharmaceutical company, saw a 19% drop in its stock in post-market trading following the announcement that its amyotrophic lateral sclerosis (ALS) study did not meet its primary objective.
The mentioned study was an evaluation of the eIF2B agonist DNL343 as a potential treatment for ALS under Regimen G of the Phase 2/3 HEALEY ALS Platform Trial.
According to the company's press release, the study did not meet the primary endpoint of demonstrating efficacy in slowing disease progression when compared to a placebo.
In addition to this, key secondary endpoints, which included measurements of muscle strength and respiratory function, did not show significant differences between the active and placebo groups at the 24-week mark.
Despite not meeting its primary and secondary objectives, DNL343 was found to be safe and well tolerated by the patients. Denali Therapeutics also mentioned that further analyses are planned for later in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.